Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of TEGSEDI in hATTR-PN
NCT04306510Phase 4Terminated
- Sponsor
- Akcea Therapeutics
- Start
- Jan 2021
- Primary completion
- Mar 2024
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
A Phase 4 trial of inotersen in hereditary transthyretin amyloidosis (hATTR), sponsored by Akcea Therapeutics. Started Jan 2021; status: terminated.
02
Drugs
inotersen
03
Conditions
hereditary transthyretin amyloidosis (hATTR)
Beyond the preview
Go deeper on NCT04306510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04306510.